Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Icilio Cavero & Henry Holzgrefe. (2014) Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative. Expert Opinion on Drug Safety 13:6, pages 745-758.
Read now
Read now
Icilio Cavero. (2013) 2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines. Expert Opinion on Drug Safety 12:4, pages 589-603.
Read now
Read now
Icilio Cavero. (2012) 2011 Annual Meeting of the Safety Pharmacology Society: an overview. Expert Opinion on Drug Safety 11:2, pages 341-353.
Read now
Read now
François Curtin & Pierre Schulz. (2011) Assessing the benefit:risk ratio of a drug - randomized and naturalistic evidence. Dialogues in Clinical Neuroscience 13:2, pages 183-190.
Read now
Read now
Icilio Cavero. (2011) 10th annual meeting of the Safety Pharmacology Society: an overview. Expert Opinion on Drug Safety 10:2, pages 319-333.
Read now
Read now
Icilio Cavero. (2010) Cardiovascular system assessment best practices: a Safety Pharmacology Society meeting. Expert Opinion on Drug Safety 9:5, pages 855-866.
Read now
Read now
Icilio Cavero. (2010) Safety Pharmacology Society: 9th Annual Meeting. Expert Opinion on Drug Safety 9:2, pages 365-378.
Read now
Read now
Articles from other publishers (25)
Shayne Cox Gad & Dexter SullivanJr.Jr.. 2023. Drug Safety Evaluation. Drug Safety Evaluation
457
476
.
Najam A. Sharif. 2022. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics
131
146
.
Christelle Froger-Colléaux, Elise Esneault, Anne Marie Hernier, Sonia Goineau & Vincent Castagné. 2022. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
1
69
.
Yashpal Singh Malik, Anuradha Sharma, Niraj Kumar Singh, B. T. Naveen Kumar & Naveen Kumar. 2022. Protocols for the Diagnosis of Pig Viral Diseases. Protocols for the Diagnosis of Pig Viral Diseases
363
377
.
Elisa Giubilato, Virginia Cazzagon, Mónica J. B. Amorim, Magda Blosi, Jacques Bouillard, Hans Bouwmeester, Anna Luisa Costa, Bengt Fadeel, Teresa F. Fernandes, Carlos Fito, Marina Hauser, Antonio Marcomini, Bernd Nowack, Lisa Pizzol, Leagh Powell, Adriele Prina-Mello, Haralambos Sarimveis, Janeck James Scott-Fordsmand, Elena Semenzin, Burkhard Stahlmecke, Vicki Stone, Alexis Vignes, Terry Wilkins, Alex Zabeo, Lang Tran & Danail Hristozov. (2020) Risk Management Framework for Nano-Biomaterials Used in Medical Devices and Advanced Therapy Medicinal Products. Materials 13:20, pages 4532.
Crossref
Crossref
Najah Abi-Gerges, Carrie McMahon, Hugo Vargas, Philip Sager, Ray Chui, Dale Stevens, Jonathan Davila, Johanna R. Schaub, Joseph C. Wu, Carlos del Rio, Chris Mathes, Paul E. Miller, Leigh Ann Burns-Naas & Andre Ghetti. (2019) The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment. Journal of Pharmacological and Toxicological Methods 98, pages 106582.
Crossref
Crossref
Eunjung Park, Gary A Gintant, Daoqin Bi, Devi Kozeli, Syril D Pettit, Jennifer B Pierson, Matthew Skinner, James Willard, Todd Wisialowski, John Koerner & Jean-Pierre Valentin. (2018) Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. British Journal of Pharmacology 175:4, pages 606-617.
Crossref
Crossref
G.B. Jena & Sapana Chavan. (2017) Implementation of Good Laboratory Practices (GLP) in basic scientific research: Translating the concept beyond regulatory compliance. Regulatory Toxicology and Pharmacology 89, pages 20-25.
Crossref
Crossref
T.J. Baird, D.V. Gauvin & J.A. Dalton. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development
155
187
.
Shayne Cox Gad. 2016. Drug Safety Evaluation. Drug Safety Evaluation
413
432
.
Christopher P. Regan, Gary L. Stump, Theodore J. Detwiler, Li Chen, Hillary K. Regan, David B. Gilberto, Joseph J. DeGeorge & Frederick J. Sannajust. (2016) Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs. Journal of Pharmacological and Toxicological Methods 81, pages 107-114.
Crossref
Crossref
E.L. Andrade, A.F. Bento, J. Cavalli, S.K. Oliveira, R.C. Schwanke, J.M. Siqueira, C.S. Freitas, R. Marcon & J.B. Calixto. (2016) Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Brazilian Journal of Medical and Biological Research 49:12.
Crossref
Crossref
Lei Shu, Gary Gintant & Lanju Zhang. 2016. Nonclinical Statistics for Pharmaceutical and Biotechnology Industries. Nonclinical Statistics for Pharmaceutical and Biotechnology Industries
177
198
.
Gary Gintant. 2015. Principles of Safety Pharmacology. Principles of Safety Pharmacology
47
64
.
Varun Ahuja & Sharad Sharma. (2014) Drug safety testing paradigm, current progress and future challenges: an overview. Journal of Applied Toxicology 34:6, pages 576-594.
Crossref
Crossref
Bernard Christophe. (2013) Simulation of early after-depolarisation in non-failing human ventricular myocytes: Can this help cardiac safety pharmacology?. Pharmacological Reports 65:5, pages 1281-1293.
Crossref
Crossref
Brian R. Berridge, Peter Hoffmann, James R. Turk, Frank Sellke, Gary Gintant, Gerald Hirkaler, Kevin Dreher, A. Eric Schultze, Dana Walker, Nick Edmunds, Wendy Halpern, James Falls, Marty Sanders & Syril D. Pettit. (2013) Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities. Regulatory Toxicology and Pharmacology 65:1, pages 38-46.
Crossref
Crossref
Theodore J. Baird, David V. Gauvin & Jill A. Dalton. 2013. A Comprehensive Guide to Toxicology in Preclinical Drug Development. A Comprehensive Guide to Toxicology in Preclinical Drug Development
107
140
.
John E. Koerner & Peter K. S. Siegl. 2013. Global Approach in Safety Testing. Global Approach in Safety Testing
243
265
.
Bernard Testa, Alessandro Pedretti & Giulio Vistoli. (2012) Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discovery Today 17:11-12, pages 549-560.
Crossref
Crossref
Jens-Uwe Peters, Jérôme Hert, Caterina Bissantz, Alexander Hillebrecht, Grégori Gerebtzoff, Stefanie Bendels, Fabien Tillier, Jacques Migeon, Holger Fischer, Wolfgang Guba & Manfred Kansy. (2012) Can we discover pharmacological promiscuity early in the drug discovery process?. Drug Discovery Today 17:7-8, pages 325-335.
Crossref
Crossref
Laszlo Urban, Steven Whitebread, Jacques Hamon, Dmitri Mikhailov & Kamal Azzaoui. 2012. Polypharmacology in Drug Discovery. Polypharmacology in Drug Discovery
15
46
.
Bruce D. Car. 2012. Polypharmacology in Drug Discovery. Polypharmacology in Drug Discovery
7
14
.
Alan S. Bass, Hugo M. Vargas, Jean-Pierre Valentin, Lewis B. Kinter, Tim Hammond, Rob Wallis, Peter K.S. Siegl & Keiji Yamamoto. (2011) Safety pharmacology in 2010 and beyond: Survey of significant events of the past 10years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods 64:1, pages 7-15.
Crossref
Crossref
Zhi Su & Gary Gintant. 2011. Heart Rate and Rhythm. Heart Rate and Rhythm
627
638
.